Replies to post #78067 on Biotech Values

[mcbio]

Re: MNTA

I agree. If the FDA approves the Lovenox ANDA from NVS/MNTA and fails to act on the ANDA’s from Teva and Amphastar, there will be some lingering doubt as to whether the FDA intends to approve the other ANDA’s. Hence, MNTA’s share price immediately following such an FDA announcement should logically stop short of the best-case number I posited in #msg-37875396.

You do still believe the stock price will be much higher from current levels even if the other generics are all approved though, correct? I realize upside will be more limited if they are but I still think the stock looks good at current levels as long approval is obtained by NVS/MNTA and irrespective of the competition.